There are no current data on the use of CAR-NK cells for MDS patients, but some trials are ongoing using allogeneic CAR-NK cells targeting NKG2D ligands (NCT04623944) and CAR.70/IL15-transduced NK cells derived from cord blood (NCT05092451). The gene discussed is KLRK1; the disease is myelodysplastic syndrome.